Related Experiment Video
Updated: Jul 6, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus
Kirsten Overoye-Chan1, Steffi Koerner, Richard J Looby
1EPIX Pharmaceuticals, 4 Maguire Road, Lexington, Massachusetts 02421, USA.
Abstract:
Thrombus (blood clot) is implicated in a number of life threatening diseases, e.g., heart attack, stroke, pulmonary embolism. EP-2104R is an MRI contrast agent designed to detect thrombus by binding to the protein fibrin, present in all thrombi. EP-2104R comprises an 11 amino acid peptide derivatized with 2 GdDOTA-like moieties at both the C- and N-terminus of the peptide (4 Gd in total). EP-2104R was synthesized by a mixture of solid phase and solution techniques. The La(III) analogue was characterized by and 1D and 2D NMR spectroscopy and was found to have the expected structure. EP-2104R was found to be significantly more inert to Gd(III) loss than commercial contrast agents. At the most extreme conditions tested (pH 3, 60 degrees C, 96 hrs), less than 10% of Gd was removed from EP-2104R by a challenge with a DTPA based ligand, while the commercial contrast agents equilibrated within minutes to hours. EP-2104R binds equally to two sites on human fibrin (Kd = 1.7 +/- 0.5 microM) and has a similar affinity to mouse, rat, rabbit, pig, and dog fibrin. EP-2104R has excellent specificity for fibrin over fibrinogen (over 100-fold) and for fibrin over serum albumin (over 1000-fold). The relaxivity of EP-2104R bound to fibrin at 37 degrees C and 1.4 T was 71.4 mM(-1) s(-1) per molecule of EP-2104R (17.4 per Gd), about 25 times higher than that of GdDOTA measured under the same conditions. Strong fibrin binding, fibrin selectivity, and high molecular relaxivity enable EP-2104R to detect blood clots in vivo.
Insights
EP-2104R is a novel MRI contrast agent that targets fibrin, a key component of blood clots. This agent demonstrates high stability, specific binding to thrombi, and enhanced relaxivity for improved in vivo clot detection.
Area of Science:
- Biochemistry
- Medical Imaging
- Materials Science
Background:
- Thrombus formation is a critical factor in life-threatening conditions like heart attack, stroke, and pulmonary embolism.
- Effective diagnostic tools for early and accurate thrombus detection remain a significant clinical need.
- Current MRI contrast agents lack specificity and stability for targeted thrombus imaging.
Purpose of the Study:
- To develop and characterize EP-2104R, a novel MRI contrast agent designed for specific thrombus detection.
- To evaluate the stability, fibrin-binding affinity, specificity, and relaxivity of EP-2104R.
- To assess the potential of EP-2104R for in vivo detection of blood clots.
Main Methods:
- Synthesis of EP-2104R using a combination of solid-phase and solution techniques.
- Characterization of the La(III) analogue using 1D and 2D NMR spectroscopy.
- Assessment of EP-2104R's inertness to Gadolinium (Gd) loss under extreme conditions compared to commercial agents.
- Evaluation of fibrin binding affinity and specificity across multiple species.
- Measurement of EP-2104R's relaxivity when bound to fibrin.
Main Results:
- EP-2104R demonstrated superior inertness to Gd(III) loss compared to commercial contrast agents, with <10% Gd loss under extreme conditions.
- High and consistent binding affinity to human and animal fibrin (Kd = 1.7 ± 0.5 µM).
- Excellent specificity for fibrin over fibrinogen (>100-fold) and serum albumin (>1000-fold).
- Significantly high molecular relaxivity (71.4 mM⁻¹s⁻¹ per molecule) when bound to fibrin, approximately 25 times higher than GdDOTA.
Conclusions:
- EP-2104R exhibits remarkable stability and high affinity for fibrin, making it a promising candidate for targeted thrombus imaging.
- Its superior specificity and enhanced relaxivity contribute to its potential for effective in vivo blood clot detection.
- EP-2104R represents a significant advancement in MRI contrast agents for diagnosing thrombotic diseases.
More Related Videos
13:10Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
Published on: September 25, 2016
06:29Cardiac Magnetic Resonance for the Evaluation of Suspected Cardiac Thrombus: Conventional and Emerging Techniques
Published on: June 11, 2019
Related Concept Videos
Imaging Studies for Cardiovascular System IV: CMRI
Magnetic Resonance Imaging
Imaging Studies I: CT and MRI
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...
Imaging Studies III: Computed Tomography
Imaging Studies for Cardiovascular System V: CT
Imaging Studies for Cardiovascular System II:Types of Echocardiography
Types of Echocardiography
Transthoracic Echocardiography (TTE)
TTE is the most common type of echocardiogram which involves placing a transducer on the patient's chest, emitting sound waves to create heart images. TTE is invaluable for evaluating the heart's size, structure, and motion, making it particularly useful for diagnosing...